• 1
    Cochran AJ,Balda BR,Starz H,Bachter D,Krag DN,Cruse CW,Pijpers R,Morton DL. The Augsburg Consensus. Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies. Cancer 2000; 89: 23641.
  • 2
    Gershenwald JE,Thompson W,Mansfield PF,Lee JE,Colome MI,Tseng CH,Lee JJ,Balch CM,Reintgen DS,Ross MI. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17: 97683.
  • 3
    Balch CM,Soong SJ,Gershenwald JE,Thompson JF,Reintgen DS,Cascinelli N,Urist M,McMasters KM,Ross MI,Kirkwood JM,Atkins MB,Thompson JA, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 362234.
  • 4
    Starz H,Balda BR,Krämer KU,Büchels H,Wang HJ. A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer 2001; 91: 211021.
  • 5
    Cherpelis BS,Haddad F,Messina J,Cantor AB,Fitzmorris K,Reintgen DS,Fenske NA,Glass LF. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas. J Am Acad Dermatol 2001; 44: 7626.
  • 6
    Starz H,De Donno A,Balda BR. The Augsburg experience: histological aspects and patient outcomes. Ann Surg Oncol 2001; 8( 9 Suppl): 48S51S.
  • 7
    Starz H,Siedlecki K,Balda BR. Sentinel lymphonodectomy and S-classification: a successful strategy for better prediction and improvement of outcome of melanoma. Ann Surg Oncol (United States) 2004; 11( 3 Suppl): 162S8S.
  • 8
    Morton DL,Hoon DS,Cochran AJ,Turner RR,Essner R,Takeuchi H,Wanek LA,Glass E,Foshag LJ,Hsueh EC,Bilchik AJ,Elashoff D, et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg 2003; 238: 53849.
  • 9
    Kretschmer L,Hilgers R,Möhrle M,Balda B-R,Breuninger H,Konz B,Kunte C,Marsch WC,Neumann C,Starz H. Patients with lymphatic metastasis of cutaneous malignant melanoma benefit from sentinel lymphonodectomy and early excision of their nodal disease. Eur J Cancer 2004; 40: 2128.
  • 10
    Gutzmer R,Al Ghazal M,Geerlings H,Kapp A. Sentinel node biopsy in melanoma delays recurrence but does not change melanoma-related survival: a retrospective analysis of 673 patients. Br J Dermatol 2005; 153: 113741.
  • 11
    Volkenandt M,Schmidt M,Konz B,Gummer M,Hein R,Plewig G,Hölzel D. Clinical and epidemiological data of patients with malignant melanoma from the Munich Tumor Center 1977–1997. Hautarzt 1999; 50: 4708.
  • 12
    Veronesi U,Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg 1991; 126: 43841.
  • 13
    Garbe C,Hauschild A,Volkenandt M,Schadendorf D,Stolz W,Kortmann R-D,Kettelhack C,Frerich B,Keilholz U,Dummer R,Sebastian G,Tilgen W, et al. Kurzleitlinie: Malignes Melanom der Haut JDDG 2006; 4: 3449.
  • 14
    Corsetti RL,Allen HM,Wanebo HJ. Thin ≤1 mm level III and IV melanomas are higher risk lesions for regional failure and warrant sentinel lymph node biopsy. Ann Surg Oncol 2000; 7: 45660.
  • 15
    Breslow A. Tumor thickness in evaluating prognosis of cutaneous melanoma. Ann Surg 1978; 187: 440.
  • 16
    Starz H,Balda B-R. Sentinel lymphonodectomy and micromorphometric S-staging, a successful new strategy in the management of cutaneous malignancies. Giorn Ital Dermatol Venereol 2000; 135: 1619.
  • 17
    Bedrosian I,Faries MB,Guerry D,Elenitsas R,Schuchter L,Mick R,Spitz FR,Bucky LP,Alavi A,Elder DE,Fraker DL,Czerniecki BJ. Incidence of sentinel node metastasis in patients with thin primary melanoma (≤1 mm) with vertical growth phase. Ann Surg Oncol 2000; 7: 2627.
  • 18
    Puleo CA,Messina JL,Riker AI,Glass LF,Nelson C,Cruse CW,Johnson TM,Sondak VK. Sentinel node biopsy for thin melanomas: which patients should be considered? Cancer Control 2005; 12: 2305.
  • 19
    Bachter D,Starz H,Volkmar Ch,Vogt H,Büchels H,Balda B-R. The sentinel-lymphonodectomy in malignant melanoma. Der Nuklearmediziner 1999; 4: 24552.
  • 20
    Starz H,Cochran AJ,Balda B-R. Histopathological aspects of the sentinel lymphonodectomy. Akt Dermatol 2002; 28: 2738.
  • 21
    Starz H. Pathology of the sentinel lymph node in melanoma. Semin Oncol 2004; 31: 35762.
  • 22
    Balda B-R,Starz H. Histological aspects of sentinel lymphonodectomy in dermato-oncology with special regard to malignant melanoma. In: TomasiniC,PippioneM, eds. Dermatopathology collection. Torino: Medical Communications, 2006; 15562.
  • 23
    Clemente CG,Mihm MC,Jr,Bufalino R,Zurrida S,Collini P,Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77: 130310.
  • 24
    Balda B-R,Starz H. Malignant melanoma. In: KatsambasAD,LottiTM, eds. European Handbook of Dermatological Treatments,2nd edn. Berlin: Springer, 2003; 3219.
  • 25
    Bleicher RJ,Essner R,Forshag LJ,Wanek LA,Morton DL. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol 2003; 21: 132631.
  • 26
    Thomas JM. Time to re-evaluate sentinel node biopsy in melanoma post-multicenter selective lymphadenectomy trial. J Clin Oncol 2005; 23: 94434.
  • 27
    Sleeman JP. The lymph node as a bridgehead in the metastatic dissemination of tumors. Rec Res Cancer Res 2000; 157: 5581.
  • 28
    Stitzenberg KB,Groben PA,Stern SL,Thomas NE,Hensing TA,Sansbury LB,Ollila DW. Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness ≤1.0 mm). Ann Surg Oncol 2004; 11: 9006.